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Abstract
Background: Erythropoietin (EPO) and its receptor play
a major role in embryonic brain, are weakly expressed in
normal postnatal/adult brain and up-regulated upon
metabolic stress. EPO protects neurons from hypoxic/
ischemic injury. The objective of this trial is to study the
safety and efficacy of recombinant human EPO (rhEPO)
for treatment of ischemic stroke in man.
Materials and Methods: The trial consisted of a safety
part and an efficacy part. In the safety study, 13 patients
received rhEPO intravenously (3.3  104 IU/50 ml/30
min) once daily for the first 3 days after stroke. In the dou-
ble-blind randomized proof-of-concept trial, 40 patients
received either rhEPO or saline. Inclusion criteria were
age 80 years, ischemic stroke within the middle cerebral
artery territory confirmed by diffusion-weighted MRI,
symptom onset 8 hr before drug administration, and
deficits on stroke scales. The study endpoints were func-
tional outcome at day 30 (Barthel Index, modified Rankin
scale), NIH and Scandinavian stroke scales, evolution of
Correspondence and reprint requests should be addressed to:
Professor H. Ehrenreich, Max-Planck-Institute for Experimental
Medicine, Hermann-Rein-Str. 3, D-37075 Goettingen, Germany.
Phone: 49 551 3899628; fax: 49 551 3899670; 
e-mail: ehrenreich@em.mpg.de.
infarct size (sequential MRI evaluation using diffusion-
weighted [DWI] and fluid-attenuated inversion recovery
sequences [FLAIR]) and the damage marker S100ß.
Results: No safety concerns were identified. Cere-
brospinal fluid EPO increased to 60–100 times that of
nontreated patients, proving that intravenously admin-
istered rhEPO reaches the brain. In the efficacy trial, pa-
tients received rhEPO within 5 hr of onset of symptoms
(median, range 2:40–7:55). Admission neurologic scores
and serum S100 concentrations were strong predictors
of outcome. Analysis of covariance controlled for these two
variables indicated that rhEPO treatment was associated
with an improvement in follow-up and outcome scales. A
strong trend for reduction in infarct size in rhEPO patients
as compared to controls was observed by MRI.
Conclusion: Intravenous high-dose rhEPO is well tolerated
in acute ischemic stroke and associated with an improve-
ment in clinical outcome at 1 month. A larger scale clinical
trial is warranted.
Introduction
Stroke remains a leading cause of death and disabil-
ity throughout the world. Currently, thrombolysis
using recombinant tissue plasminogen activator
(rTPA) is the only pharmacologic treatment with
Clinical Trial
acceptable side effects shown to effectively limit
neurologic damage in acute stroke (1). Use of rTPA
is mainly restricted to those patients who present
less than 3 hr after the onset of a nonhemorrhagic
stroke, leaving 90% of stroke patients without
specific treatment. Any successful effort to develop a
widely applicable treatment of stroke, complemen-
tary and/or alternative to rTPA, would therefore be
of major clinical importance.
Although, apart from clot-dissolving strategies,
a variety of agents targeting different aspects of
stroke pathology appear effective in animal models,
successful translation of any to the treatment of hu-
man stroke has proven elusive. Recently, attention
has focused on potential therapeutic roles for en-
dogenous brain proteins possessing neuroprotec-
tive properties. Erythropoietin (EPO), a member of
the growth hormone/prolactin cytokine family (2),
is one promising candidate. Although EPO was first
characterized by and is now widely known for its
role as a hematopoietic hormone (3), the detection
of EPO and its receptor (EPOR) in rodent and hu-
man brain tissue (4–7) as well as in cultured neu-
rons (8,9) and astrocytes (6,9,10) expanded the
search for other biological roles of EPO. EPO gene
expression in most tissues, including the brain, is
oxygen-dependent and regulated by hypoxia-
inducible factor-1 (3). We have recently observed
dramatic changes in the expression of EPO and its
receptor localized to regions within and around in-
farcts in human brain following ischemic/hypoxic
injury (11). Similar observations have been ob-
tained in animal models (12). EPO is also neu-
rotrophic in model systems and marked changes in
EPO gene expression are a prominent feature of
normal brain development (5).
Several research groups have reported that EPO
added to neuronal cultures protects against hypoxic
and glutamic acid toxicity (7,8,12) and when 
directly administered into the brain reduces neuro-
logic dysfunction in rodent models of stroke
(4,12–15). Furthermore, neutralization of endoge-
nous brain EPO potentiates ischemic brain injury
(14), confirming a pivotal role for the endogenous
EPO system in neuronal survival after ischemia. 
Finally, inflammatory cells (16,17) have been shown
to express EPOR; thus, EPO may play important
roles in modulating the inflammatory response to
injury.
We recently showed that EPO does not require
intrathecal administration to provide effective neu-
roprotection; systemically delivered recombinant
human (rh) EPO reduces infarct volume by about
75% in a rodent model of middle cerebral artery
(MCA) stroke (4). The biological basis of this neu-
roprotection includes the inhibition of neuronal
apoptosis within potentially viable peri-infarct re-
gion (penumbra) (15). In this rodent model, rhEPO
is neuroprotective when administered 24 hr before
arterial occlusion as well as up to 3 hr afterwards.
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Partial efficacy is seen as late as 6 hr following the
induction of ischemia.
Over the past decade, rhEPO has been admin-
istered to millions of patients, many with associ-
ated serious medical conditions, as a highly effica-
cious and safe treatment for anemia. Considering
these preclinical and clinical data, rhEPO is an 
attractive candidate to evaluate as a therapy for 
human stroke. The aims of the present study were
to determine whether the use of rhEPO in acute
stroke is safe and whether administration of rhEPO
in human stroke is beneficial over a 30-day follow-
up period. We find that rhEPO administered intra-
venously at high doses to patients with docu-
mented acute stroke within the MCA territory is
well tolerated and safe. Further, in a double-
blind study, rhEPO administered intravenously
within 8 hr of the onset of ischemic symptoms signif-
icantly hastens improvement of neurologic function
and ameliorates stroke-related disability assessed at
30 days.
Patients and Methods
The study protocol was approved by the Ethical
Committee of the Georg-August-University of Goet-
tingen, Germany. Since December 1998, a total of
53 patients have been included in this first study
evaluating the use of rhEPO in treating human
stroke. The trial consisted of two consecutive parts.
After inclusion of 13 patients in the safety study
with open-label rhEPO administration (erythro-
poietin-ß; Roche, Grenzach-Wyhlen, Germany),
the study was switched to a double-blind placebo-
controlled proof-of-concept trial. Study endpoints
were sequential neurologic scoring using the NIH
and Scandinavian stroke scales (SSS), clinical out-
come ratings at day 30 as assessed by Barthel index
and modified Rankin scale, lesion size at days 1, 3,
and 18 as determined by MRI and the serum marker
of brain injury, S100 (18,19). Additional clinical
variables collected on days 1, 3, 7, 18, and 30 in-
cluded serum EPO, hematocrit, hemoglobin, leuko-
cyte and thrombocyte counts, partial prothrombin
time (PTT), C-reactive protein (CRP), ferritin, trans-
ferrin, iron, electrolytes, glucose, blood urea nitro-
gen (BUN), and creatinine.
Inclusion Criteria
To facilitate determination of the imaging endpoints
(a comparative measurement of affected brain area
by MRI) only patients with an ischemic stroke in
the MCA were accepted. Inclusion further required
a definitive temporal onset of symptoms, allowing
for rhEPO infusion within 8 hr, as well as neuro-
logic deficits using the stroke scales. A cranial com-
puterized tomography (CT) scan was performed to
first exclude any kind of hemorrhage. An acute
stroke was confirmed using diffusion-weighted
MRI (DWI), whereas fluid-attenuated inversion
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in the setting of an acute stroke and, further, whether
rhEPO crosses the blood–brain barrier into the
brain. Characteristics of the 13 patients enrolled in
the safety study are summarized in Table 1. Cere-
brospinal fluid (CSF) was obtained from four safety
study patients with stroke in the MCA territory to
whom rhEPO was administered as an intravenous
infusion of 3.3  104 IU/50 ml/30 min on 3 consecu-
tive days after stroke (total dose 100,000 IU), starting
within 8 hr of initial stroke symptoms. The chosen
dosage had been among the highest doses tested in
clinical trials at the time the study was designed and
proven to be well tolerated (20). CSF sampling was
performed on day 2, at 6.4  5.2 (mean  SEM) hr
after the second infusion. For comparison, CSF was
also obtained from two patients (a 68-year-old man,
and a 74-year-old woman) of the intensive care unit
who had an acute stroke in the MCA territory (36 and
48 hr ago), happened to have a lumbar puncture
for diagnostic reasons but were not in the EPO study
and had not received rhEPO, and from 6 neurologic
disease controls (essentially healthy patients under-
going a diagnostic evaluation for migraine or lower
back pain and who also did not receive rhEPO).
Double-Blind Proof-of-Concept Study
Forty patients were enrolled in the double-blind
proof-of-concept study. For blinding, a pharmacist
recovery (FLAIR) sequences should essentially be
free of fresh infarct signs and rule out a recent infarct
in the same territory. Enrollment was limited to pa-
tients less than 80 years old, and informed consent
by patient, entitled relatives, or an independent
physician was required.
Exclusion Criteria
Exclusion criteria were defined in part to facilitate
evaluation of the study by homogenizing the sample
population, as well as in consideration of the lite-
rature on rhEPO application in other indications.
They included any contraindication to MRI, unclear
onset of clinical signs, quickly resolving neurologic
symptoms, coma or pre-coma, previous infarction
within the same arterial territory, brain trauma or
surgery within the last 4 weeks, subarachnoid or
intracerebral hemorrhage, intracranial neoplasia,
septic embolism, endocarditis, malignant hyperten-
sion, florid malignancy, myeloproliferative disorder,
polycythemia, allergy against rhEPO, serum creati-
nine 3 mg/dl, hyperkalemia, follow-up for 30 days
not guaranteed, or recent participation in other ther-
apeutic trials.
Safety Study
The safety study goals were to provide data to assess
whether intravenously administered rhEPO was safe
Table 1. Baseline characteristics of the patients in the two parts of the study
Part I: Safety
rhEPO rhEPO Placebo
(n  13) (n  21) (n  19) f
Age (years; median, range) 68(21–78) 68(39–80) 63(49–79) n.s.
Sex (male/female) 8/5 15/6 13/6 n.s.
Hemisphere (left/right) 5/8 11/10 10/9 n.s.
Stroke subtype
Cardioembolic 6 9 10 n.s.
Small vessel occlusive 4 3 3 n.s.
Large vessel occlusive 1 5 4 n.s.
Other 2 4 2 n.s.
ASA pretreatment 7 5 9 n.s.
Stroke scales
SSS (median, range) 31(9–46) 30(8–52) 30(6–54) n.s.
NIHSS (median, range) 12(4–27) 11(3–26) 11(1–28) n.s.
Imaging
DWI (cm3; mean  SEM) — 40.1  11.8 35.4  8.0 n.s.
FLAIR (cm3; mean  SEM) — 14.1  8.5 3.8  1.3 n.s.
Mean arterial blood pressure 122(109–145) 127(91–150) 130(100–177) n.s.
(mm Hg; median, range)
CRP (U/I; mean  SEM) 4.3  0.8 13.3  6.6 9.0  4.6 n.s.
Glucose (mg%; mean  SEM) 146.7  19.9 123.5  8.7 137.2  14.0 n.s.
Time to treatment (h:min) 6:20(3:30–8:00) 5:00(2:40–7:55) 4:45(3:20–7:45) n.s.
(median, range)
Part II: Double-Blind
prepared and numbered identical vials containing
either saline (0.9% NaCl) or EPO reconstituted in
saline. The vials were randomly assigned to patients
upon enrollment with the contents of each vial known
only by the pharmacist. None of the clinicians per-
forming neurologic or imaging analyses had access to
any of the serum laboratory data obtained (platelet
or reticulocyte counts) during the study. Serum EPO
levels were analyzed only after unblinding the
study. Study groups turned out to be highly compa-
rable with respect to baseline characteristics, with
no significant differences in age, sex, hemisphere in-
volved, NIHSS, SSS scores or DWI lesion size upon
enrollment (Table 1). Time to treatment was slightly
better as compared to the safety study, due to im-
provements in enrollment management, but did not
differ significantly between treatment groups, nor
did pretreatment of patients with aspirin or pre-
sumed stroke etiology differ. In addition, pre-existing
risk factors as determined by medical history were
not different in the two groups. Also, blood pressure
upon admission, glucose, and C-reactive protein
levels in serum were comparable.
Study Design
A history and physical examination were obtained
for every stroke patient screened for participation in
the study, followed by a routine laboratory evalua-
tion and cranial CT scan before being referred to
MRI. Following initial MRI, the final decision upon
inclusion was made based on the criteria delineated.
Intravenous infusion of rhEPO (3.3  104 IU/50 ml/
30 min) was started immediately thereafter, in all
cases within the first 8 hr after onset of symptoms
(day 1). EPO was administered again 24  and 48 hr
later to provide a cumulative dose of 100,000 IU of
rhEPO for each stroke patient. For the control arm of
the study, saline (0.9% NaCl) was used as placebo.
MRI data were also obtained on days 3 and 18. Neu-
rologic scoring and laboratory tests were performed
on days 1 (before treatment), 3, 7, 18, and 30 fol-
lowing stroke onset. For determination of EPO in
serum, an additional blood sample was taken 3 hr
after each rhEPO infusion. Blood pressure was mea-
sured on days 1, 2, and 3 on the left arm with the pa-
tient maintained in a 30° head up tilt immediately
before and 5, 15, 30, 60, 120, and 180 minutes after
the start of the rhEPO infusion.
S100ß Assay
Serum concentrations of S100ß, a glial marker
of brain damage (18), were determined using 
the LIAISON-Sangtec-S100 assay (Byk-Sangtec 
Diagnostica, Diezenbach, Germany). The sensitivity
of the assay is 0.02 g/l. Normal serum concentra-
tions of S100ß are 0.12 g/l.
Erythropoietin ELISA
Concentrations of EPO were measured in serum
(efficacy study) and in paired samples of CSF and
498 Molecular Medicine, Volume 8, Number 8, August 2002
serum (safety study) using a commercially available
ELISA kit (R&D Systems, Wiesbaden, Germany)
according to the manufacturer’s protocol. Serum
samples of the double-blind study were not ana-
lyzed before unblinding of the study. CSF from con-
trol subjects was concentrated by drying 2 ml of CSF
overnight under nitrogen, and the sample rediluted
with the sample diluent (included in the kit) to the
final volume of 120 l. This procedure improved
the sensitivity of the kit allowing measurement
of EPO in normal CSF (lower limit of detection
0.2 mU/ml). For determination of fractional recov-
ery, paired samples (n  3) of CSF and CSF spiked
with 20 l of the 50 mU/ml rhEPO standard (included
in the kit) were dried, rediluted, and measured in
parallel with a recovery of 95%, 112%, and 102%.
MRI Evaluation of Lesion Size
MRI data were obtained on days 1, 3, and 18. During
each session, DWI and FLAIR images were produced,
consisting of 16 and 20 comparable horizontal sec-
tions, respectively. To determine the lesion size and
its evolution over time, a standard volumetric proce-
dure was performed using the EasyVision software
(CT/MR Release 2.1 Level 5, Philips Medical Sys-
tems, Best, The Netherlands) on a Sun workstation.
Data Analysis
Primary endpoints evaluated were neurologic scores
(NIH and SSS) and functional outcome at day 30
(Barthel’s and modified Rankin). Secondary end-
points were time-dependent changes in the neuro-
logic scores and serum marker of injury (S100)
over 30 days, as well as infarct size at days 3 and 18
as assessed by DWI and FLAIR. Several considera-
tions guided the approach to the data analysis. First,
the wide range of severity of stroke at enrollment
(NIHSS range of 1–28) contributed a major share of
the data variance because the neurologic score is the
major determinant of both outcome and lesion size,
as has been reported by many studies (21,22). Sec-
ond, early evaluation of infarct size can be accurately
obtained by use of MRI and serum markers which
increase by day 3 (22,23). Of these, S100, a product
of activated astroglia and oligodendrocytes, is a
marker released in proportion to the size of the in-
farct, with a clear biological relevance to inflamma-
tion and injury (18,24). Further, S100 has been
shown to predict neurobehavioral outcome after
stroke (19). Multiple regression analysis was per-
formed with the outcome measures serving as de-
pendent variables, and treatment as the independent
variable, with admission stroke score and S100
concentration on day 3 as covariates in the analysis.
Inclusion of other covariates such as age or time to
treatment did not change the results of the analysis.
Ordinal data (Barthel and modified Rankin) were
analyzed using logistical methods. Furthermore,
Mann-Whitney U-test, Fisher exact probability test,
or independent Student’s t-test were used where
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and the imaging analysis (Fig. 4), patients were
censored at death since individual data points are
presented or required.
Results
Of the 320 stroke patients screened for participation
in the trial, less than 20% (n  53) fulfilled the
enrollment criteria. The most common reasons for ex-
clusion were time to treatment longer than 8 hr, in-
farcts outside the MCA territory, contraindications to
MRI, older than 80 years, or quickly resolving neuro-
logic symptoms consistent with a transient ischemic
attack. About half of the patients enrolled had a car-
dioembolic etiology (Table 1).
Safety Study
Baseline characteristics of patients studied are sum-
marized in Table 1. Intravenous infusion of rhEPO
(3.3  104 IU/50 ml/30 min) was started within the
first 8 hr (median 6 hr 20 min; range 3 hr 30 min to 
8 hr) after onset of symptoms (day 1) and was read-
ministered 24 hr and 48 hr later (days 2 and 3).
Serum levels of rhEPO obtained 3 hr after each
rhEPO infusion rose to a mean  SD of 4132  561,
4794  1183, and 5649  903 mU/ml on days 1, 2,
and 3, respectively, which was not associated with
any changes in blood pressure. The hematocrit, he-
moglobin, and red blood cell counts remained stable
throughout the 30-day observation period. Simul-
taneous samples of the CSF of patients receiving
rhEPO contained EPO at a concentration more
than 60 times greater (17.1  5.6 mU/ml, n  4)
than samples obtained from two nontreated stroke
patients (0.7 mU/ml and 0.3 mU/ml) or patients with
other neurologic conditions (0.3  0.06 mU/ml, n  6)
(p  0.01).
Double-Blind Proof-of-Concept Study
Figure 1A illustrates that the study groups were
highly comparable in terms of baseline stroke sever-
ity. In the efficacy study, three deaths occurred, one
within the placebo arm (day 6, malignant brain
edema as a consequence of progressive stroke re-
sulting in total infarction of the left MCA territory)
and two within the rhEPO arm (day 17 and day 27
from pneumonia, sepsis, multi-organ failure). Time
to drug infusion was 5 hr (range 2 hr 40 min to 7 hr
55 min) for rhEPO and 4 hr 45 min (range 3 hr 
20 min to 7 hr 45 min) for placebo. The use of intra-
venous heparin during the course of the study was
not different between the two groups (placebo,
11/19; rhEPO, 11/21). Other admission values, in-
cluding S100 and stroke scores, were not signifi-
cantly different (Table 1).
Serum EPO concentrations obtained for the first
nine rhEPO-treated patients rose to a mean of 5148 
1094 mU/ml (Table 2) and were not associated with
blood pressure changes. Follow-up neurologic scor-
ings obtained on days 3, 7, 18, and 30, using the NIH
indicated. A percentile distribution analysis, origi-
nally devised for the quantitative evaluation of
cerebral infarct volume (25), was applied both to
evolution of the lesion size (DWI) and to the NIHSS.
Briefly, the scores within each treatment group were
ranked in an ascending order and the ranks were con-
verted into percentiles. Individual scores were dis-
played as a function of the percentile rank within
their group, whereas scores of each group were
matched according to their corresponding percentile
rank. This allows a quantitative display of individ-
ual data points, revealing the spectrum of change be-
tween groups. Three patients died during the course
of the study. None of the deaths was related to treat-
ment. They occurred much later in the course of
post-stroke complications. In the clinical analysis
(NIHSS, SSS, Barthel, and Rankin), dead patients re-
ceived the worst possible score, which actually tends
to worsen the results of the study (Figs. 2 and 3).
In the percentile distribution analysis (Figs. 1 and 5)
Fig. 1. Percentile distribution analysis of NIH stroke scale
for placebo and rhEPO-treated patients (A) upon admission
(baseline); (B) at day 30 after treatment. Note the remarkable
dissociation of curves over time for moderately to severely 
affected patients.
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and Scandinavian stroke scales, expectedly agreed
well. Nevertheless, because of inherent differences
in the rating of severely affected comatose patients,
the relationship between NIHSS score and SSS score
is not linear: In the NIHSS, motor function is scored
in all extremities, whereas in the SSS only motor
function of the affected side is rated. This explains
the slightly different results obtained with the two
scales (Fig. 2 A and B). In fact, the rhEPO-treated
patients improved earlier with the largest difference
between the treatment groups occurring on day 18
(score differences of 9 in the SSS and 4 in the
NIHSS; Fig. 2 A and B). The Scandinavian stroke
scale data showed an earlier improvement, with a
significant difference evident by day 7. The better
course of the rhEPO-treated patients continued
throughout the remaining study period. A generally
similar pattern was obtained using the NIHSS,
except that a significant improvement was only
observed on day 18 (p  0.03) and was maintained
to day 30 (p  0.09). The diminished separation be-
tween the treatment groups in both stroke scales at
day 30 appears to depend on an improvement in the
placebo arm scores (Fig. 2 A and B). Percentile dis-
tribution analysis of the NIHSS illustrates a clear sep-
aration between treatment groups at day 30 (Fig. 1B).
Fig. 2. Functional recovery of patients
in the double-blind proof-of-concept
trial. (A) NIH stroke scale. (B) Scandina-
vian stroke scale. Data represent mean 
SEM (n  19 for placebo, n  21 for
rhEPO). p-Values according to multiple
regression analysis. Dead patients received
the worst possible score.
Fig. 3. Clinical outcome of patients in the double-blind proof-of-concept trial. (A) Barthel index (rhEPO versus placebo 
p  0.05). (B) Modified Rankin scale (rhEPO versus placebo p  0.07) on day 30. Dead patients received the worst possible score.
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(p  0.05). As shown in Figure 3A, at 1 month 42%,
of the placebo patients were severely affected (score
20), compared to 14% of the rhEPO-treated pa-
tients. Further, the percentage of patients with a
good outcome (score 80) was 57% in the rhEPO
group compared to 42% in the placebo group. Simi-
lar results were obtained for the modified Rankin
scale with 37% of the placebo patients severely
affected (score 5–6) compared to 14% of the rhEPO
patients (Fig. 3B). The results of the modified
Rankin evaluation, however, failed to reach statisti-
cal significance (p  0.07).
Serial MRI data are presented in Figure 4. A 
superior course in rhEPO versus placebo patients was
evident in the DWI on day 18 (p  0.05). Inspection
of the percentile distribution analysis of the DWI
data (Fig. 5) shows a distinct dissociation between
groups in respect to evolution of lesion volume. The
serum marker of infarct damage, S100, was identi-
cal in both groups on admission to the trial and
increased after time of infarct, peaking by day 7. The
rhEPO group peaked at a lower level and earlier
than the placebo group and thereafter returned to
within the normal range sooner (Fig. 6). At day 30,
serum S100 of the rhEPO-treated group had nor-
malized, whereas those of the placebo treated group
remained elevated (p  0.05).
Selected follow-up laboratory parameters are
presented in Table 2. The hematocrit and red blood
cell counts did not increase to levels exceeding the
normal range in rhEPO patients. There was only a
tendency toward higher levels of these parameters
in the rhEPO-treated group as compared to controls.
In contrast, the hematocrit of placebo-treated pa-
tients fell slightly. As expected, the reticulocyte
count increased to 29.2  10.0% in rhEPO-treated
patients, peaking at day 7 and normalizing there-
after (data not shown). Thrombocyte counts showed
comparable increases by day 18 in both treatment
groups.
The subgroup of mildly affected patients is, how-
ever, likely to have a good recovery independent of
the treatment arm. The clinical outcome evaluation
performed using the Barthel index also showed a
significantly superior outcome after rhEPO treatment
Fig.4  Evolution of lesion size of 
patients in the efficacy trial. (A) DWI.
(B) FLAIR. Data represent mean  SEM.
p-Value according to multiple regression
analysis. Dead patients have been 
censored.
Fig. 5. Percentile distribution analysis of DWI for placebo and
rhEPO-treated patients (A) upon admission (baseline); (B) at
day 18 after treatment. Note the remarkable dissociation of
curves over time for moderately to severely affected patients.
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Discussion
Although a number of therapeutic trials for stroke
have been undertaken in the past decade, no broadly
applicable, safe, and efficacious treatment has been
identified (26–28). The present data support a novel
approach to neuroprotection of cerebral ischemic in-
jury by use of rhEPO, clinically one of the best-
characterized and well-tolerated therapeutics. The
clear-cut results of this trial supporting a signifi-
cantly better recovery of rhEPO-treated versus
placebo-treated patients with respect to the clinical
endpoints of stroke and outcome scales, coupled
with a faster normalization in the circulating serum
marker of injury, S100, and a more favorable out-
come in MRI data, compelled us to report these re-
sults despite the relatively small number of patients
studied thus far.
It is important to note that only one patient re-
cruited into this study could be administered rhEPO
within the critical 3 hr time window found for 
effective rTPA therapy (1), which is, apart from as-
pirin, the only currently approved protective treat-
ment for acute stroke. The 3-hr time window is
likely of critical relevance for rhEPO as well, be-
cause programmed cell death, one target of rhEPO
therapy (15), is initiated within 3 hr after infarction
(29). We have evaluated this issue in detail using a
rodent model of MCA stroke, for which administra-
tion of a single dose of rhEPO 3 hr after occlusion is
as effective as when given at occlusion, but is only
50% as active if delayed to 6 hr. By 9 hr after occlu-
sion, rhEPO is without neuroprotective benefit in
rats (4). In retrospect, not much can be said about a
potential influence of a late inclusion time point in
the present study. In the double-blind (efficacy)
part, the time to treatment was much shorter than
the designated 8-hr time window in most patients.
In fact, only two patients in each group were in-
cluded after 6 hr of onset of symptoms. Although
time course and sequence of pathophysiologic events
contributing to the evolution of ischemic lesion may
be somewhat different in man and rat, it is a distinct
possibility that patients administered rhEPO within
3 hr of stroke onset would experience an even better
outcome than observed in the present study.
Although a variety of in vivo and in vitro studies
show that EPO is also protective of excessive (neuro-
toxic) excitation (4,14), the protection observed here
appears to mainly target later events (e.g., apoptosis
or inflammation subsequent to brain injury) (4). In
fact, rhEPO will likely provide significant protection
only within the penumbra and not within the is-
chemic core. Pathologic/regenerative processes of
longer latency than examined in this study may also
be beneficially affected (15,30). Whether the more
rapid improvement noted in the rhEPO treatment
group will be maintained over longer periods of 
follow-up will need testing by conducting additional
clinical trials. Prerequisite for the use of peripherally
applied rhEPO in stroke was to demonstrate the
availability of this large (34,000-dalton) molecule in
the brain after intravenous infusion. The results of the
safety study confirmed that intravenous administra-
tion of a total of 100,000 IU of rhEPO after a docu-
mented stroke led to a 60- to 100-fold increase in CSF
EPO levels. Interestingly, our rat experiments suggest
that movement of EPO into the CSF does not even re-
quire a breakdown of the blood–brain barrier: Peak
concentrations of EPO in CSF from the cisterna
magna after intraperitoneal injection amount to
0.5–1% that of serum at around 3.5 hr (unpublished
observations).
The use of the neurochemical serum marker,
S100, provides valuable information concerning
nervous tissue injury. Although the biological func-
tion of S100 is not entirely clear, its release into the
circulation is associated with secretion by reactive
astrocytes and functional disturbances of mem-
brane integrity (31). The normalization of S100 after
30 days for the rhEPO arm but not the placebo arm
may suggest that the inflammatory processes and/or
blood–brain barrier integrity improve more rapidly
or completely after rhEPO administration.
For statistical analysis of the data, it was neces-
sary to control for the admission stroke score as well
as the S100 levels at day 3, as both have been
shown to be strong predictors of outcome (19,21).
Because the admission stroke scores and day 3 S100
serum levels were similar in both patient groups, a
similar outcome would be predicted, in contrast with
the findings of this study. The results of the per-
centile distribution analysis of NIHSS and DWI data
(Figs. 1 and 5) do not only demonstrate a clear dis-
sociation of curves upon the respective later time
point but also suggest that the predominant effect of
Fig. 6. Time course of serum S100 levels in placebo and
rhEPO-treated patients over the 30-day follow-up period.
Data represent mean  SEM. Mann-Whitney U-test. The dashed
line denotes normal serum concentration.




















































































































































































































































































































































































































































































































































EPO is within the moderately to severely affected 
patients.
Several design factors are likely responsible for
the relative success of this small trial. The rigorous
enrollment criteria for this study—selection of pa-
tients suffering from infarcts of the MCA territory only
(for comparability of clinical and imaging data)—led
to the inclusion in our center of less than 20% of
the stroke patients, at the price of extending the du-
ration of the study. Another advance of the present
trial, and unique thus far (despite recent recommen-
dations of MRI for early diagnosis of stroke [32]), are
the three MRI sessions, on days 1 (emergency MRI),
3, and 18 (follow-up MRIs). These guarantee not only
the exclusion of patients with transitory ischemic at-
tacks (no signs in DWI) but also a more objective es-
timation of the real time window (DWI positive and
FLAIR still essentially negative as inclusion criteria).
On the other hand, at least one factor may have de-
creased the discriminative power of this study: the
median severity of stroke upon admission was less
than that in the only successful large scale trial to date
(NIHSS of 11 versus 14) (1), whereas it was identical
to the ECAAS II study (33). The enrollment of mildly
affected patients seemingly reduced the magnitude of
the beneficial effect in our study (Fig. 1B). It will
therefore have to be considered to define a NIHSS
cutoff (presumably 5) for inclusion of patients in
follow-up studies.
The results of this study are fully consistent with
the efficacy of rhEPO observed in animal models of
ischemic brain injury. The clear results obtained us-
ing a small group of patients with moderately severe
strokes suggest that the effects of rhEPO are robust.
Thus, a formal clinical efficacy trial will not likely
require an excessively large enrollment. The avail-
ability of an apparently safe agent that can be given
hours after the onset of ischemia will need confir-
mation by a larger trial with longer follow-up. Con-
firmation of these findings will then provide the 
basis for a generally applicable therapy for acute is-
chemic stroke.
Stroke therapy with rhEPO is not primarily aim-
ing at re-opening of the feeding artery. This is the
domain of rTPA and related substances. The neuro-
protective approach using EPO is aimed at protect-
ing potentially viable brain tissue from the spread-
ing of death signals. EPO will in the future be of
great value to add to the effect of clot-dissolving
strategies and may even reduce reperfusion injury.
The fact that a beneficial action can already be
demonstrated in a pure neuroprotective study should
actually be even more encouraging. Undoubtedly, a
successful stroke therapy in the future will have to be
a combined therapy. The present work prepares a
hopeful ground for the neuroprotective part of this
strategy. In other words, EPO is not a competitor of
but complement to rTPA. In cases with contraindica-
tion to lysis (still 90% of strokes), EPO alone will
provide an alternative.
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